Articles related to IMMUNOTHERAPY

First-line pembrolizumab and pembrolizumab-chemotherapy continued to outperform cetuximab-chemotherapy in recurrent/metastatic head and neck squamous cell carcinoma after a 4-year follow-up. Following pembrolizumab-based therapy, patients responded well to subsequent treatment.

An ASCO Reading Room selection Fascinating work defining new therapeutic targets and cutting-edge treatment approaches in gynecological cancer is about to come. In this abstract, the authors go over new therapies for gynecologic cancers, such as endometrial, cervical, ovarian, and uncommon gynecologic tumors, and highlight studies that have improved clinicians’ knowledge of the distinct biology and molecular foundations of different tumors, which is being used to develop potent new therapeutic modalities.

Until a tumor is determined to be TMB-high or MSI-H/MMRd, and thus qualifies for treatment with pembrolizumab or dostarlimab on the basis of cancer site-agnostic approval, there is no justification for the use of single-agent ICB in unselected populations with recurrent EOC. However, the clinical trials carried out up to this point show that ICB can induce long-lasting responses in a relatively small fraction of individuals. These discoveries offer opportunities and challenges to the medical and scientific communities, including the need to use novel technologies to locate predictive biomarkers and create immunotherapies that go beyond ICB to improve the effectiveness of these drugs.

This review summarizes the clinical presentation, workup, staging, and recent advancements in the treatment of PCNSL. Although treatment advances include the use of BTK inhibitors and immunomodulators, relapse is common and 5-year survival is 40% or lower. Thus, accurate early diagnosis and initiation of treatment is time sensitive for optimal neurologic recovery and disease control.

With two cycles of neoadjuvant immunotherapy, nearly every patient with mismatch repair-deficient (dMMR) colon cancer in the NICHE-2 trial achieved a pathologic response. At a median follow-up of 13.1 months, the disease-free survival (DFS) rate was 100% vs. an expected rate for this patient population of 15%.

168 adults with unresectable stage IIIC-IV melanoma with progression after 1 line of systemic treatment (not including ipilimumab) were randomly assigned to receive tumor-infiltrating lymphocyte therapy or ipilimumab. With a median follow-up of nearly 3 years, the median PFS was 7.2 months in the TIL arm and 3.1 months in the ipilimumab arm.